Semnur Pharmaceuticals, Inc.
SMNR · OTCMCIK 1913577fmd_1VT4Z6ZK4DXQ2CYG968VBX2BCGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 05, 2022 to Sep 30, 2026, 19 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Research and development | – | – | 2 | 3 |
| Total operating expenses | – | – | 5 | 160 |
| Operating income | – | (3) | (5) | (160) |
| Interest expense | – | 0 | 0 | – |
| Interest and investment income | 1 | 4 | 2 | – |
| Income before taxes | – | – | 0 | 0 |
| Income tax expense | – | – | 0 | 0 |
| Net income from continuing operations | – | – | 0 | 0 |
| Net income | (0) | 1 | (5) | (160) |